WO2009063843A1 - ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 - Google Patents

ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 Download PDF

Info

Publication number
WO2009063843A1
WO2009063843A1 PCT/JP2008/070457 JP2008070457W WO2009063843A1 WO 2009063843 A1 WO2009063843 A1 WO 2009063843A1 JP 2008070457 W JP2008070457 W JP 2008070457W WO 2009063843 A1 WO2009063843 A1 WO 2009063843A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
subject
obesity
body fat
fat mass
Prior art date
Application number
PCT/JP2008/070457
Other languages
English (en)
French (fr)
Inventor
Satoshi Inoue
Tomohiko Urano
Yasuyoshi Ouchi
Masataka Shiraki
Original Assignee
The University Of Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tokyo filed Critical The University Of Tokyo
Publication of WO2009063843A1 publication Critical patent/WO2009063843A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

　肥満を早期に予期しうる遺伝的マーカーを開発し、メタボリックシンドロームをはじめとする肥満関連疾患の予防に寄与する。ヒト被験者のゲノムＤＮＡを含む試料を用いて、ＳＬＣ２５Ａ２４遺伝子、ＯＤＺ３遺伝子、ＫＩＡＡ１７９７遺伝子、ＤＬＤ遺伝子、ＬＯＣ４４１２８２遺伝子、ＯＮＥＣＵＴ２遺伝子、ＮＰＡＳ３遺伝子、ＡＣＣＮ１遺伝子、ＴＧＭ２遺伝子、ＦＡＭ４４Ｂ遺伝子、ＥＳＲＲＧ遺伝子、ＬＲＰ１Ｂ遺伝子、ＦＧＦ１０遺伝子、ＫＩＡＡ１６００遺伝子、ＡＦＴＰＨ遺伝子、及びＤＡＰＫ１遺伝子に存在する特定の一塩基多型（ＳＮＰ）、又はそれらと連鎖不平衡にある遺伝子多型を検出することを含み、当該遺伝子多型又はその組み合わせは、前記被験者の成人後における体脂肪量が増加しやすいか否かを示唆する。
PCT/JP2008/070457 2007-11-16 2008-11-11 ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 WO2009063843A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007298045A JP5427352B2 (ja) 2007-11-16 2007-11-16 ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法
JP2007-298045 2007-11-16

Publications (1)

Publication Number Publication Date
WO2009063843A1 true WO2009063843A1 (ja) 2009-05-22

Family

ID=40638692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070457 WO2009063843A1 (ja) 2007-11-16 2008-11-11 ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法

Country Status (2)

Country Link
JP (1) JP5427352B2 (ja)
WO (1) WO2009063843A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131491A1 (ja) * 2009-05-15 2010-11-18 国立大学法人東京大学 肥満素因の評価方法及びキット、並びに、抗肥満薬及びそのスクリーニング方法、非ヒト動物、脂肪組織、脂肪細胞、トランスジェニックマウス作成方法、抗原、抗体
ITPD20110258A1 (it) * 2011-08-03 2013-02-04 Univ Cagliari Metodo per la valutazione farmacogenetica della risposta al trattamento con sali di litio nel disturbo bipolare
CN113699115A (zh) * 2021-08-13 2021-11-26 中山大学附属第八医院（深圳福田） Dapk1在调控人骨髓来源msc的成脂分化能力中的用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954724B2 (ja) * 2011-07-25 2016-07-20 国立研究開発法人理化学研究所 第６染色体短腕２２領域または第９染色体長腕２１領域の一塩基多型に基づく肥満の検査方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003265200A (ja) * 2002-03-19 2003-09-24 Pharma Design Inc 高トリグリセリド血症、肥満及び高血圧症に対する易罹患性の判定方法
JP2006136267A (ja) * 2004-11-15 2006-06-01 Japan Health Science Foundation 遺伝子診断法による太りやすさの判定方法、および抗肥満薬のスクリーニング方法
WO2006134154A2 (en) * 2005-06-17 2006-12-21 Centre National De La Recherche Scientifique (Cnrs) Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213274A1 (en) * 2005-12-20 2007-09-13 Oy Jurilab Ltd Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
WO2007086526A1 (ja) * 2006-01-27 2007-08-02 National University Corporation Kanazawa University 遺伝子多型およびその用途
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003265200A (ja) * 2002-03-19 2003-09-24 Pharma Design Inc 高トリグリセリド血症、肥満及び高血圧症に対する易罹患性の判定方法
JP2006136267A (ja) * 2004-11-15 2006-06-01 Japan Health Science Foundation 遺伝子診断法による太りやすさの判定方法、および抗肥満薬のスクリーニング方法
WO2006134154A2 (en) * 2005-06-17 2006-12-21 Centre National De La Recherche Scientifique (Cnrs) Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
URANO T. ET AL.: "Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women.", J. BONE MINER METAB., vol. 25, no. 4, 2007, pages 253 - 258 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131491A1 (ja) * 2009-05-15 2010-11-18 国立大学法人東京大学 肥満素因の評価方法及びキット、並びに、抗肥満薬及びそのスクリーニング方法、非ヒト動物、脂肪組織、脂肪細胞、トランスジェニックマウス作成方法、抗原、抗体
US8877443B2 (en) 2009-05-15 2014-11-04 The University Of Tokyo Method and kit for evaluation of predisposition to development of obesity, anti-obesity agent and method for screening thereof, non-human animal, adipose tissue, adipocyte, method for production of transgenic mouse, antigen, and antibody
ITPD20110258A1 (it) * 2011-08-03 2013-02-04 Univ Cagliari Metodo per la valutazione farmacogenetica della risposta al trattamento con sali di litio nel disturbo bipolare
WO2013017661A1 (en) * 2011-08-03 2013-02-07 Universita' Degli Studi Di Cagliari Method for the assessment of pharmacogenetic response to treatment with lithium salts in bipolar disorder
CN113699115A (zh) * 2021-08-13 2021-11-26 中山大学附属第八医院（深圳福田） Dapk1在调控人骨髓来源msc的成脂分化能力中的用途
CN113699115B (zh) * 2021-08-13 2023-09-22 中山大学附属第八医院（深圳福田） Dapk1在调控人骨髓来源msc的成脂分化能力中的用途

Also Published As

Publication number Publication date
JP2009118803A (ja) 2009-06-04
JP5427352B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
Keele et al. Genetic fine‐mapping and identification of candidate genes and variants for adiposity traits in outbred rats
De Chaudhuri et al. Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+ 3) methyltransferase, and glutathione S-transferase omega genes
Li Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease
Lesseur et al. A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire
Lin et al. Polymorphisms of arsenic (+ 3 oxidation state) methyltransferase and arsenic methylation capacity affect the risk of bladder cancer
NZ588037A (en) Serotonin transporter gene SLC6A4 and treatment of alcoholism
WO2009073345A3 (en) Assay for detecting genetic abnormalities in genomic nucleic acids
NZ628598A (en) Vegf polymorphisms and anti-angiogenesis therapy
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
NZ598009A (en) Genetic markers associated with risk of diabetes mellitus
Stensvold et al. Limited intra-genetic diversity in Dientamoeba fragilis housekeeping genes
NZ701432A (en) Improved method and kit for determining severity and progression of periodontal disease
NZ591711A (en) A method for predicting athletic performance potential
JP2011530312A5 (ja)
WO2009063843A1 (ja) ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法
EP1988178A3 (en) Nucleotide primer set and nucleotide probe for detecting genotype of serum amyloid A1(SAA1)
WO2011020906A3 (en) sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
Dwyer et al. Mutation screening of the DTNBP1 exonic sequence in 669 schizophrenics and 710 controls using high‐resolution melting analysis
WO2008048902A8 (en) Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
WO2008065544A3 (en) Genetic predictors of risk for type 2 diabetes mellitus
WO2009007726A3 (en) Abnormal blood conditions
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
WO2012024189A3 (en) Compositions and methods for determining predisposition to developing metabolic syndrome
RU2010149541A (ru) Способ прогнозирования развития метаболического синдрома у пациента с абдоминальным ожирением

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848856

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08848856

Country of ref document: EP

Kind code of ref document: A1